Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)
Evidence-based consensus statements for the identification and management of interstitial lung disease in systemic sclerosis
Hoffamnn-Vold AM et al.
Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD): further analyses of the SENSCIS trial
Khanna D et al.
Effects of nintedanib in patients with extensive and limited systemic sclerosis-associated ILD (SSc-ILD): further analyses of the SENSCIS trial
Denton CP et al.
Does dose adjustment affect decline in forced vital capacity in patients treated with nintedanib? Data from the SENSCIS trial
Mayes MD et al.
Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) over 100 weeks: data from the SENSCIS trial
Assassi S et al.
Prevalence and clinical presentation of SSc-associated ILD according to worldwide spatial repartition in the EUSTAR database
Lescoat A et al.
Which treatment aspects matter to patients with systemic sclerosis associated interstitial lung disease? The development of a patient preference instrument
Saketkoo LA et al.
Disease frequency and characteristics of patients diagnosed with systemic sclerosis and systemic sclerosis associated interstitial lung disease: a US cohort study
Li Q et al.
Immunosuppressant treatments and clinical outcomes among patients with systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study
Li Q et al.
Management and burden of disease of SSc-ILD in eight European countries: results of the BUILDUP project
Wuyts W et al.
Systemic sclerosis (SSc) with interstitial lung disease (SSc-ILD) in Canada’s largest province: an estimate of the prevalence and survival of SSc and SSc-ILD in Ontario over 10 years
Pope JE et al.
The patient journey of SSc-ILD in Europe: an integrated analysis of healthcare professional and patient perspectives
Hoffmann-Vold AM et al.